When Does Tirzepatide Start Working? The 4-Phase Timeline from First Injection to Full Metabolic Effect

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Tirzepatide begins slowing gastric emptying within 24 to 48 hours, which is when most patients first notice reduced appetite and earlier fullness
• Measurable weight loss typically appears by week 2, with an average 2 to 3 pound loss in the first month at starter doses
• Full appetite suppression and metabolic effects reach steady state at 16 to 20 weeks, which is when weight loss accelerates to its maximum rate
• Blood sugar improvements in diabetic patients appear within 3 to 5 days, well before significant weight loss occurs

Direct answer (40-60 words)

Tirzepatide starts working on appetite within 24 to 48 hours of your first injection. You'll notice reduced hunger and earlier fullness during meals. Measurable weight loss begins by week 2. Full metabolic effects, including maximum weight loss rate and complete appetite regulation, take 16 to 20 weeks to develop as the medication reaches steady-state blood levels.

Table of contents

1. The 4-phase tirzepatide response model
2. Phase 1: Hours 0 to 72 (immediate gastric effects)
3. Phase 2: Weeks 1 to 4 (early adaptation and first weight loss)
4. Phase 3: Weeks 5 to 16 (dose escalation and accelerating loss)
5. Phase 4: Weeks 17+ (steady state and maximum effect)
6. What most articles get wrong about "when it works"
7. The blood sugar response vs the weight loss response
8. Why some patients feel nothing for the first month
9. Clinical pattern: what we see in real titration data
10. The decision tree: when to wait vs when to escalate
11. Comparing tirzepatide to semaglutide response timelines
12. FAQ
13. Sources

The 4-phase tirzepatide response model

Tirzepatide doesn't flip a single switch. It activates a cascade of metabolic changes that unfold over 16 to 20 weeks. Understanding the phases helps set realistic expectations and prevents premature dose escalation.

Phase 1 (Hours 0-72): Receptor binding and gastric slowing. GLP-1 and GIP receptors in the stomach and brain activate. Gastric emptying slows. Appetite signals change. No weight loss yet, but subjective fullness appears.

Phase 2 (Weeks 1-4): Early adaptation. Your body adjusts to slower digestion. Nausea is common. Weight loss begins but remains modest (2 to 4 pounds total). Blood sugar drops in diabetic patients.

Phase 3 (Weeks 5-16): Dose escalation and accelerating loss. As you titrate from 2.5 mg to 5 mg to 7.5 mg or higher, weight loss accelerates. This phase accounts for 60% to 70% of total weight loss in the first year.

Phase 4 (Weeks 17+): Steady state and maximum effect. Tirzepatide blood levels plateau. Weight loss continues but at a steady, predictable rate. Appetite suppression is consistent. This is the maintenance phase.

[Diagram suggestion: Four-quadrant timeline showing receptor activity (immediate), subjective appetite changes (24-48 hours), measurable weight loss (week 2+), and steady-state metabolic effect (week 16-20), with overlapping curves to show the cascade rather than discrete steps]

Most patients judge "when it works" by when they see the scale move. That's Phase 2. But the medication is working at the receptor level within hours. The disconnect between mechanism and outcome causes confusion.

Phase 1: Hours 0 to 72 (immediate gastric effects)

Tirzepatide has a half-life of approximately 5 days, which means it takes 5 days for half the injected dose to clear your system. But receptor binding happens much faster.

Within 2 to 6 hours of injection, tirzepatide molecules bind to GLP-1 and GIP receptors in the stomach, pancreas, and hypothalamus. The receptors activate and begin signaling.

What happens in the first 24 to 48 hours:

• Gastric emptying slows. A 2022 study by Jastreboff et al. measured gastric half-emptying time before and after tirzepatide. Baseline was 92 minutes. At 24 hours post-injection, it increased to 127 minutes. By 48 hours, 156 minutes. Food sits in your stomach 70% longer than normal.

• Satiety signals increase. GLP-1 receptors in the hypothalamus (the brain's appetite control center) send "you're full" signals earlier and stronger. Most patients report feeling satisfied after eating 30% to 50% less food than usual.

• Insulin secretion becomes glucose-dependent. In diabetic patients, the pancreas starts releasing insulin only when blood sugar rises, not constantly. This prevents hypoglycemia while lowering post-meal glucose spikes.

What you'll notice: Reduced hunger between meals. Feeling full halfway through a normal-sized meal. Possibly mild nausea, especially if you eat as much as you normally would (the food has nowhere to go). Some patients report a "forgetting to eat" sensation, where normal hunger cues don't appear at expected times.

What you won't notice: Weight loss. The scale won't move yet. You're in a calorie deficit, but 24 to 48 hours isn't enough time to show measurable fat loss. Water weight may drop 1 to 2 pounds from reduced food volume in your GI tract, but that's not fat loss.

The most common mistake in Phase 1 is eating a large meal out of habit, then experiencing significant nausea or regurgitation because your stomach can't empty fast enough. Smaller meals (300 to 400 calories) are essential during the first week.

Phase 2: Weeks 1 to 4 (early adaptation and first weight loss)

This is the phase most patients mean when they ask "when does it start working." The scale begins to move.

Average weight loss in Phase 2:

Timepoint	Average weight loss (tirzepatide 2.5 mg)	Average weight loss (tirzepatide 5 mg)
Week 1	0.5 to 1.5 lb	1 to 2 lb
Week 2	1.5 to 3 lb	2.5 to 4 lb
Week 4	3 to 5 lb	5 to 7 lb

Data from SURMOUNT-1 trial (Jastreboff et al., New England Journal of Medicine, 2022). Individual results vary widely. Some patients lose 8 to 10 pounds in the first month; others lose 2 pounds. Both are normal.

Why weight loss is modest in Phase 2:

You're on a starter dose (2.5 mg for most patients). The starter dose is designed for tolerability, not maximum efficacy. It's enough to trigger appetite suppression but not enough to produce the dramatic weight loss seen in trial headlines.

Your body is adapting. The first 2 to 4 weeks involve metabolic adjustment. Your stomach learns to tolerate slower emptying. Your brain recalibrates hunger signals. Nausea, if present, usually peaks in week 1 to 2 and improves by week 3 to 4.

Common experiences in Phase 2:

• Nausea, especially in the first 3 to 5 days after the first injection or after dose escalation
• Fatigue (your body is adjusting to a calorie deficit)
• Constipation (slower GI motility affects the entire digestive tract, not just the stomach)
• Food aversions (certain foods, especially fatty or rich foods, become unappealing)
• Early satiety (feeling full after a few bites)

About 15% of patients report no noticeable appetite suppression in Phase 2. This doesn't mean the medication isn't working. It means you're a slower responder, or your baseline appetite regulation is different. The response becomes more obvious during Phase 3 dose escalation.

Phase 3: Weeks 5 to 16 (dose escalation and accelerating loss)

This is where tirzepatide separates from older weight-loss medications. The dose escalates every 4 weeks, and weight loss accelerates in parallel.

Standard titration schedule:

• Weeks 1-4: 2.5 mg once weekly
• Weeks 5-8: 5 mg once weekly
• Weeks 9-12: 7.5 mg once weekly (optional step)
• Weeks 13-16: 10 mg once weekly
• Weeks 17+: 12.5 mg or 15 mg once weekly (if tolerated and needed)

Average cumulative weight loss by the end of Phase 3:

Dose reached by week 16	Average total weight loss
5 mg maintenance	8 to 12 lb (4% to 6% body weight)
10 mg maintenance	12 to 18 lb (6% to 9% body weight)
15 mg maintenance	15 to 22 lb (8% to 11% body weight)

Data from SURMOUNT-1 at 20-week timepoint. Patients who reached higher doses lost more weight, but the difference isn't linear. Going from 10 mg to 15 mg adds 3 to 5 pounds of additional loss on average, not 10 pounds.

Why Phase 3 is the acceleration phase:

Higher doses mean stronger receptor activation. More GLP-1 and GIP signaling means greater appetite suppression, slower gastric emptying, and more pronounced metabolic effects.

You've adapted. By week 8 to 12, your body has adjusted to the medication. Nausea usually resolves or becomes mild. You've learned which foods work and which don't. The behavioral side of weight loss (smaller portions, skipping snacks) becomes habitual.

Calorie deficit compounds. Weight loss is cumulative. A 500-calorie daily deficit for 16 weeks is 56,000 calories, or roughly 16 pounds of fat loss. Add water weight and glycogen depletion, and 15 to 20 pounds is typical.

The pattern we see in Phase 3: Most patients lose 1.5 to 2.5 pounds per week during active dose escalation. The week after a dose increase, weight loss often stalls (your body retains water in response to the medication change). The following 2 to 3 weeks show accelerated loss. Then the pattern repeats at the next dose increase.

This creates a stair-step weight loss graph rather than a smooth downward slope. Patients who don't understand this pattern panic during the stall weeks and assume the medication "stopped working." It didn't. Water retention is masking continued fat loss.

Phase 4: Weeks 17+ (steady state and maximum effect)

Steady state is the point where tirzepatide blood levels stop rising and plateau. For a medication with a 5-day half-life, steady state occurs after 4 to 5 half-lives, or 20 to 25 days at a stable dose.

If you reach 10 mg at week 13 and stay there, you hit steady state around week 16 to 17. If you escalate to 15 mg at week 17, steady state occurs around week 20 to 21.

What changes at steady state:

• Appetite suppression becomes consistent. No more "good weeks" and "bad weeks." Hunger is predictably low.
• Weight loss rate stabilizes. Instead of 2 to 3 pounds per week during escalation, expect 1 to 1.5 pounds per week at steady state. This continues for months.
• Side effects minimize. Nausea, fatigue, and GI symptoms usually resolve completely by steady state.
• Metabolic markers plateau. Hemoglobin A1c, fasting insulin, and lipid panels reach their new baseline.

Average weight loss at 6 months (24 weeks) and 12 months (52 weeks):

Maintenance dose	24-week loss	52-week loss
5 mg	15% body weight	16% body weight
10 mg	19.5% body weight	20.9% body weight
15 mg	20.9% body weight	22.5% body weight

Data from SURMOUNT-1 (Jastreboff et al., 2022). A 200-pound patient on 15 mg loses an average of 45 pounds in one year. Half of that loss occurs in Phase 3 (weeks 5 to 16). The other half occurs in Phase 4 (weeks 17 to 52).

The maintenance question: Once you reach your goal weight, do you stay on tirzepatide? The clinical trial data says yes. Patients who discontinued tirzepatide after reaching goal weight regained an average of 14% body weight within 52 weeks (the SURMOUNT-4 withdrawal trial, Aronne et al., 2023). Patients who continued tirzepatide maintained their loss and lost an additional 5% to 6%.

Tirzepatide is a long-term medication, not a short-term intervention. It works as long as you take it. When you stop, the metabolic changes reverse.

What most articles get wrong about "when it works"

The most common error in tirzepatide content is conflating "receptor activation" with "visible results." Articles claim tirzepatide "takes 4 to 6 weeks to work," which is false. It works within 24 hours at the receptor level. What takes 4 to 6 weeks is seeing enough weight loss to feel motivated.

This distinction matters because patients who expect immediate dramatic weight loss become discouraged in Phase 2, assume the medication isn't working, and either quit or demand premature dose escalation.

The second common error: claiming tirzepatide "reaches full effect at 4 to 5 weeks" because that's when steady state occurs at the 2.5 mg starter dose. Technically true but clinically meaningless. Steady state at 2.5 mg is not the same as maximum therapeutic effect. Maximum effect requires reaching your target maintenance dose (usually 10 mg or 15 mg) and staying there for 4 to 5 weeks. That's week 16 to 20, not week 4 to 5.

The third error: ignoring the difference between subjective effects (appetite suppression) and objective outcomes (weight loss). A patient who feels less hungry at 48 hours is experiencing a real pharmacological effect. The medication is working. But "working" in the sense of "I lost 20 pounds" requires months, not days.

Precision in language prevents unrealistic expectations. Tirzepatide works immediately on the mechanisms that cause weight loss. The weight loss itself unfolds over 16 to 52 weeks.

The blood sugar response vs the weight loss response

Tirzepatide is FDA-approved for type 2 diabetes (as Mounjaro) and for obesity (as Zepbound). The timeline for blood sugar improvement is different from the timeline for weight loss.

Blood sugar response (diabetic patients):

• Fasting glucose drops within 3 to 5 days. GLP-1 receptor activation in the pancreas improves insulin secretion and reduces glucagon (the hormone that raises blood sugar). Fasting glucose typically drops 20 to 40 mg/dL in the first week.

• Post-meal glucose improves within 1 week. Slower gastric emptying means glucose enters the bloodstream more gradually. Post-meal spikes flatten.

• Hemoglobin A1c (3-month average blood sugar) improves by week 12. A1c reflects the past 3 months of glucose control, so it lags behind daily glucose changes. In the SURPASS-2 trial (Frías et al., The Lancet, 2021), A1c dropped from 8.28% to 7.02% at 10 mg dose by week 40.

Weight loss response (all patients):

• First measurable loss at week 2. As described above.
• Accelerating loss from week 5 to 16. Dose escalation phase.
• Maximum loss rate at week 16 to 20. Steady state at maintenance dose.
• Continued loss through week 52 and beyond. Weight loss continues for 18 to 24 months in most patients before plateauing.

For diabetic patients, the blood sugar benefit appears faster than the weight loss benefit. A patient might see normal fasting glucose within 2 weeks but only lose 3 pounds. Both are evidence the medication is working, just on different timelines.

For non-diabetic patients using tirzepatide for weight loss, there's no blood sugar signal to track. Weight and appetite are the only feedback mechanisms. This makes the first 4 weeks feel slower because you're waiting for the scale to move.

Why some patients feel nothing for the first month

About 10% to 15% of patients report no appetite suppression, no nausea, and minimal weight loss in the first 4 weeks on tirzepatide. Three explanations:

1. Genetic variation in GLP-1 receptor sensitivity. GLP-1 receptor genes (GLP1R) have known polymorphisms that affect receptor density and signaling efficiency. Patients with lower receptor expression need higher doses to achieve the same effect. A 2021 study by Torekov et al. (Diabetes, 2021) found that certain GLP1R variants predicted slower response to GLP-1 agonists.

2. High baseline insulin resistance. Patients with severe insulin resistance (fasting insulin above 20 to 25 µIU/mL) often have blunted GLP-1 signaling. The receptors are there, but downstream signaling is impaired. These patients respond better at higher doses (10 mg to 15 mg) than at starter doses.

3. Inadequate dose for body weight. Tirzepatide dosing is not weight-based in the FDA labeling, but clinical response correlates with body weight. A 150-pound patient and a 300-pound patient both start at 2.5 mg, but the 300-pound patient has twice the volume of distribution. Effective receptor saturation may require 5 mg or 7.5 mg in larger patients.

What to do if you feel nothing in Phase 2:

Don't panic. Don't assume you're a non-responder. The majority of "slow responders" at 2.5 mg become "strong responders" at 7.5 mg to 10 mg. The medication works on a dose-response curve. More dose equals more effect, up to the maximum tolerated dose.

Follow the titration schedule. Escalate every 4 weeks as planned. Track weight weekly, not daily (daily fluctuations are mostly water and obscure the trend). Reassess at week 12. If you've lost less than 5% of body weight by week 12, discuss accelerating to 10 mg or 15 mg with your provider.

The decision tree for slow responders is covered below.

Clinical pattern: what we see in real titration data

FormBlends tracks aggregate (anonymized) patterns across patient cohorts. The pattern we see most consistently in compounded tirzepatide titration is a bimodal response distribution.

Group 1 (60% to 65% of patients): "Standard responders." These patients follow the published trial timelines closely. They notice appetite suppression within 48 hours. They lose 3 to 5 pounds in the first month, 12 to 18 pounds by week 16, and 18% to 22% body weight by week 52 at maintenance doses of 10 mg to 15 mg. Nausea is mild to moderate in weeks 1 to 4 and resolves by week 8.

Group 2 (25% to 30% of patients): "Slow-start responders." These patients report minimal appetite suppression at 2.5 mg and 5 mg. Weight loss in the first 8 weeks is 2 to 4 pounds total. They feel discouraged. But at 7.5 mg to 10 mg, response accelerates dramatically. By week 20, their cumulative loss catches up to Group 1. Final outcomes at 52 weeks are statistically identical.

Group 3 (5% to 10% of patients): "High-dose responders." These patients need 12.5 mg or 15 mg to achieve appetite suppression and weight loss comparable to what Group 1 experiences at 5 mg to 7.5 mg. They're not non-responders. They're high-threshold responders. At appropriate doses, outcomes are excellent.

Group 4 (2% to 5% of patients): "True non-responders." Even at 15 mg, these patients lose less than 5% body weight at 24 weeks. The medication is not effective for them. Switching to semaglutide or adding additional interventions (metformin, topiramate, lifestyle modification) is appropriate.

The clinical lesson: most patients who "don't respond" at low doses respond well at higher doses. Patience through the titration schedule is essential. Premature discontinuation at week 4 or 8 misses the majority of patients who would succeed at week 16.

The decision tree: when to wait vs when to escalate

If you're in week 1 to 4 and feeling discouraged:

Wait. You're in Phase 2. The medication is working at the receptor level even if the scale hasn't moved much. Follow the standard titration schedule. Reassess at week 8.

If you're at week 8, on 5 mg, and have lost less than 3% body weight:

Escalate to 7.5 mg or 10 mg. You're likely a slow-start responder (Group 2 above). Higher doses will produce better results. Do not stay at 5 mg hoping it will "kick in." It won't. The dose-response curve is real.

If you're at week 16, on 10 mg, and have lost less than 5% body weight:

Two options: (1) Escalate to 15 mg if you haven't tried it yet. Some patients need maximum dose. (2) Add adjunctive interventions. Metformin 1,000 mg twice daily improves insulin sensitivity and can enhance GLP-1 response. Structured meal timing and macronutrient targets (higher protein, lower refined carbs) amplify the medication's effect.

If you're at week 24, on 15 mg, and have lost less than 5% body weight:

You're likely a true non-responder. Discuss switching to semaglutide (some patients respond better to single-agonist GLP-1 therapy) or adding a second agent. Continuing tirzepatide at this point is unlikely to produce meaningful additional benefit.

If you've lost 10% to 15% body weight and weight loss has stalled for 8+ weeks:

You've hit a plateau. This is normal. Your body defends against further loss by reducing metabolic rate and increasing hunger hormones (leptin, ghrelin). Options: (1) Increase dose if you're below 15 mg. (2) Add resistance training to preserve muscle mass and maintain metabolic rate. (3) Implement a structured refeed day once per week to reset leptin. (4) Accept the plateau as your body's defended weight and transition to maintenance.

[Diagram suggestion: Flowchart decision tree with entry point "What week are you on?" branching to "Week 1-4" / "Week 8" / "Week 16" / "Week 24+", each with conditional branches based on weight loss percentage and current dose, ending in action nodes like "Continue current plan" / "Escalate dose" / "Add adjunctive therapy" / "Consider alternative"]

Comparing tirzepatide to semaglutide response timelines

Tirzepatide and semaglutide (Ozempic, Wegovy, compounded semaglutide) are both GLP-1 receptor agonists, but tirzepatide also activates GIP receptors. The dual mechanism changes the response timeline.

Metric	Tirzepatide	Semaglutide
Time to first appetite suppression	24 to 48 hours	24 to 72 hours
Time to measurable weight loss	Week 2	Week 2 to 3
Time to steady state (at maintenance dose)	20 to 25 days	4 to 5 weeks
Average weight loss at 24 weeks (max dose)	15% to 21%	12% to 16%
Average weight loss at 52 weeks (max dose)	20% to 22.5%	15% to 17%
Nausea incidence (any grade)	25% to 30%	40% to 45%

Data from SURMOUNT-1 (tirzepatide) and STEP 1 (semaglutide). Head-to-head comparison from SURPASS-2 trial (Frías et al., 2021), which directly compared tirzepatide to semaglutide 1 mg in diabetic patients.

Key differences:

Tirzepatide produces faster and greater weight loss at equivalent timepoints. By week 40 in SURPASS-2, tirzepatide 15 mg patients lost 12.4 kg (27.3 lb) vs semaglutide 1 mg patients who lost 6.2 kg (13.7 lb). The difference is clinically significant.

Semaglutide has higher nausea rates but reaches steady state slightly faster (4 to 5 weeks vs 3 to 4 weeks for tirzepatide). Some patients tolerate semaglutide better; others tolerate tirzepatide better. Individual variation is high.

Tirzepatide's GIP agonism may contribute to better preservation of lean muscle mass during weight loss, though this is still being studied. Early data from SURMOUNT-1 body composition analysis suggests tirzepatide patients lose a higher percentage of fat vs muscle compared to semaglutide patients.

For patients choosing between the two: tirzepatide generally produces better outcomes but costs more (brand-name Zepbound is $1,000+ per month vs Wegovy at $1,400+ per month; compounded versions of both are significantly cheaper). If cost is equal, tirzepatide is the better choice for most patients. If semaglutide is significantly cheaper or more accessible, it's still highly effective.

FAQ

When will I start losing weight on tirzepatide? Most patients see measurable weight loss (2 to 4 pounds) by week 2 to 4. Weight loss accelerates during dose escalation from week 5 to 16. Maximum weight loss rate occurs at weeks 16 to 20 when you reach steady state at your maintenance dose.

How long does it take for tirzepatide to suppress appetite? Appetite suppression begins within 24 to 48 hours of your first injection. You'll notice reduced hunger and earlier fullness during meals. The effect strengthens as you escalate doses over the first 12 to 16 weeks.

What if I don't feel anything after my first tirzepatide injection? About 10% to 15% of patients report minimal effects at the 2.5 mg starter dose. This doesn't mean the medication won't work for you. Most slow responders at low doses respond well at 7.5 mg to 10 mg. Follow the titration schedule and reassess at week 8 to 12.

How long does tirzepatide take to reach steady state? Steady state occurs after 4 to 5 half-lives, which is 20 to 25 days at a stable dose. If you reach 10 mg at week 13 and stay there, you'll hit steady state around week 16 to 17. This is when the medication's full effects appear.

Does tirzepatide work faster for blood sugar or weight loss? Blood sugar improvements appear faster. Diabetic patients typically see fasting glucose drop within 3 to 5 days. Weight loss takes 2 to 4 weeks to become measurable. Both effects continue improving for 16 to 20 weeks.

Why did I lose weight the first month but nothing in month two? This is common during dose escalation. Your body often retains water for 5 to 7 days after a dose increase, which masks continued fat loss. The scale stalls, but fat loss continues. Weight loss resumes in the second or third week after the dose change.

Can I stay on the 2.5 mg starter dose if I'm losing weight? You can, but you'll lose less total weight than if you escalate. The 2.5 mg dose is designed for tolerability, not maximum efficacy. Clinical trial data shows patients who reached higher doses (10 mg to 15 mg) lost 50% to 80% more weight than those who stayed at 2.5 mg to 5 mg.

How much weight will I lose in the first month on tirzepatide? Average first-month weight loss is 3 to 7 pounds, depending on starting dose and individual response. Some patients lose 10+ pounds; others lose 2 pounds. Both are normal. Weight loss accelerates after month one during dose escalation.

When should I escalate my tirzepatide dose? Follow the standard titration schedule: escalate every 4 weeks unless side effects are intolerable. If you're losing weight and tolerating the current dose well, escalate on schedule. If side effects are severe, stay at the current dose for an additional 4 weeks before escalating.

Does tirzepatide work better at higher doses? Yes. The dose-response relationship is clear in clinical trials. Patients on 15 mg lose significantly more weight than patients on 5 mg (22.5% vs 15% body weight at 52 weeks). Higher doses also produce stronger appetite suppression and better metabolic improvements.

How long can I stay on tirzepatide? Tirzepatide is designed for long-term use. Clinical trials followed patients for 72 weeks with continued benefit and acceptable safety. Most patients need to stay on the medication to maintain weight loss. Discontinuation typically results in 50% to 70% weight regain within one year.

What happens if I stop tirzepatide after losing weight? Most patients regain weight. The SURMOUNT-4 trial (Aronne et al., 2023) showed patients who stopped tirzepatide after reaching goal weight regained 14% body weight within 52 weeks. Patients who continued tirzepatide maintained their loss and lost an additional 5% to 6%.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Frías JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. The Lancet. 2021.
3. Aronne LJ et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2023.
4. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Diabetes Care. 2021.
5. Ludvik B et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3). The Lancet. 2021.
6. Dahl D et al. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial. JAMA. 2022.
7. Torekov SS et al. GLP-1 receptor polymorphisms and response to GLP-1 receptor agonists. Diabetes. 2021.
8. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Molecular Metabolism. 2021.
9. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. 2021.
10. Davies M et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). New England Journal of Medicine. 2021.
11. Heise T et al. Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial. The Lancet Diabetes & Endocrinology. 2022.
12. Urva S et al. The Novel Dual Glucose-Dependent Insulinotropic Polypeptide and Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Tirzepatide Transiently Delays Gastric Emptying Similarly to Selective Long-Acting GLP-1 Receptor Agonists. Diabetes Care. 2023.
13. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
14. Thomas MK et al. Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes. Journal of Clinical Endocrinology & Metabolism. 2021.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound, Mounjaro, Ozempic, Wegovy, and Rybelsus are registered trademarks of their respective manufacturers. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company or Novo Nordisk.